<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172987</url>
  </required_header>
  <id_info>
    <org_study_id>17103</org_study_id>
    <secondary_id>I8F-MC-GPGR</secondary_id>
    <nct_id>NCT04172987</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants</brief_title>
  <official_title>Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how the body processes the commonly prescribed birth
      control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and
      the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side
      effects that may occur will also be collected.

      Screening is required within 28 days prior to the start of the study. For each participant,
      the study will last about 20 weeks, including screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">February 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 24 hours post-dose</time_frame>
    <description>PK: AUC(0-tau) of EE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of EE</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 48 hours post-dose</time_frame>
    <description>PK: Cmax of EE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC(0-tau) of Norelgestromin (NGMN)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 24 hours post-dose</time_frame>
    <description>PK: AUC(0-tau) of NGMN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Norelgestromin (NGMN)</measure>
    <time_frame>Periods 1 and 2 on Day 21: Pre-dose through 48 hours post-dose</time_frame>
    <description>PK: Cmax of NGMN</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EE and NGM (active tablets) administered orally for 21 days, then non-active tablets administered orally for 7 days. (1 course of oral contraceptive = 28 days.)
Tirzepatide administered by subcutaneous injection (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE/NGM</intervention_name>
    <description>Combination oral contraceptive administered orally</description>
    <arm_group_label>EE/NGM + Tirzepatide (Period 2)</arm_group_label>
    <arm_group_label>Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy females as determined by medical history, physical examination, and
             other screening procedures

          -  Have a body mass index (BMI) equal to or above 18.5 kilograms per meter squared
             (kg/mÂ²), at screening

          -  Are not intending to start a family within 2 months after the study

        Exclusion Criteria:

          -  Have known allergies to either tirzepatide or ethinylestradiol or norgestimate or
             related compounds

          -  Have a medical condition or medical history that precludes the taking of combined oral
             contraceptives

          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or
             idiopathic acute pancreatitis), elevation in serum amylase or lipase or
             gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder
             disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery,
             pyloric stenosis, with the exception of appendectomy) or could be aggravated by
             glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors

          -  Have used hormonal implants or received hormonal injections in the past 12 months

          -  Unwilling to comply with smoking restrictions during the study

          -  Is a known user of drugs of abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>469-513-6727</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

